Preliminary evidence for sustained efficacy of CFTR modulator therapy with concomitant rifabutin administration
Journal of Cystic Fibrosis · 2024
DOI: 10.1016/j.jcf.2023.11.015 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Cystic Fibrosis, 2024. Verfasst von Eunjin Hong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, 1985 Zonal Ave, Los Angeles,…. Hauptthemen laut MEDLINE: Rifabutin, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Aminophenols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Cystic Fibrosis Foundation.
Abstract (Originalsprache)
The concomitant use of elexacaftor/tezacaftor/ivacaftor (ETI) and strong CYP3A inducers including rifampin and rifabutin is not recommended due to the risk of drug-drug interactions (DDI). This presents a significant challenge to the treatment of non-tuberculous mycobacteria precluding the first line treatment. While rifabutin induces CYP3A activity, its effect appears to be moderate compared to rifampin. In this study, we investigated three cases in which concomitant use of rifabutin and CFTR modulators (ETI or ivacaftor monotherapy) was used, and these cases suggest that addition of rifabutin did not compromise the efficacy of ETI or ivacaftor as evidenced by pulmonary function and sweat chloride testing. A full physiologically based pharmacokinetic model predicted lung concentrations of ETI upon rifabutin coadministration to exceed the half-maximal effective concentrations (EC50) determined from chloride transport in phe508del human bronchial epithelial cells. This study provides preliminary evidence in support of the use of rifabutin in patients receiving ETI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, 1985 Zonal Ave, Los Angeles, CA 90033, United States; College of Pharmacy, CHA University, 335 Pan…
- Children's Hospital of The King's Daughters, 601 Children's Ln, Norfolk, VA 23507, United States.
- Department of Pharmaceutical Services, University of California Los Angeles, 757 Westwood Plaza, Los Angeles, CA 90095, United States.
- Division of Infectious Diseases, University of California Los Angeles, 757 Westwood Plaza, Los Angeles, CA 90095, United States.
- Division of Pulmonary and Critical Care Medicine, University of California Los Angeles, 1260 15(th) St #600, Santa Monica, CA 90404, United States.
- Department of Clinical Pharmacy, Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, 1985 Zonal Ave, Los Angeles, CA 90033, United States; USC Anton Yelchin CF Clinic, 1510 San Pablo…
Förderung
- Cystic Fibrosis Foundation
Zitieren
APA
Hong, E., Parsons, S. M., Sass, L., Epstein, C., Chan, L., Brown, C., Eshaghian, P. H., & Beringer, P. M. (2024). Preliminary evidence for sustained efficacy of CFTR modulator therapy with concomitant rifabutin administration. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2023.11.015
Vancouver
Hong E, Parsons SM, Sass L, Epstein C, Chan L, Brown C, et al. Preliminary evidence for sustained efficacy of CFTR modulator therapy with concomitant rifabutin administration. Journal of Cystic Fibrosis. 2024. doi:10.1016/j.jcf.2023.11.015
BibTeX
@article{Hong2024,
author = {Hong, Eunjin and Parsons, Sarah M and Sass, Laura and Epstein, Cynthia and Chan, Lynn and Brown, Claire and Eshaghian, Patricia H and Beringer, Paul M},
title = {Preliminary evidence for sustained efficacy of CFTR modulator therapy with concomitant rifabutin administration},
journal = {Journal of Cystic Fibrosis},
year = {2024},
doi = {10.1016/j.jcf.2023.11.015}
}
EUVIMED